{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:39:11Z","timestamp":1793691551118,"version":"4.5.1"},"reference-count":88,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>The NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome has emerged as a critical mediator in cardiovascular diseases, connecting cholesterol crystals and metabolic danger signals to atherogenic inflammation, myocardial injury, and adverse remodeling. Using direct inhibitors that bind to NLRP3 has advantages over indirect strategies. These advantages include retaining the function of other inflammatory body sensors and the potential for oral treatment. Several synthetic compounds have progressed to clinical trials. Recently, NT-0796 demonstrated a significant reduction in C-reactive protein in obese patients with cardiovascular risk, and VTX2735 has entered Phase II trials for recurrent pericarditis. However, the clinical failure of MCC950 due to hepatotoxicity underscores persistent translational challenges in this field. Oridonin is the most rigorously validated natural product that covalently modifies NLRP3 at Cys279. However, most reported \u201cnatural NLRP3 inhibitors\u201d did not bind biochemically. This review demonstrates a three-tier evidence classification that differentiates confirmed direct inhibitors from functional modulators. We critically explored the potential for cardiovascular applications and identified bioavailability limitations, biomarker gaps, and trial design challenges that require innovative solutions.<\/jats:p>","DOI":"10.3389\/fphar.2026.1861169","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:45:03Z","timestamp":1782276303000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Direct NLRP3 inflammasome inhibitors for cardiovascular therapeutics: a comparative review of synthetic and natural candidates"],"prefix":"10.3389","volume":"17","author":[{"given":"Dong","family":"Zhen","sequence":"first","affiliation":[{"name":"Tongliao People\u2019s Hospital","place":["Tongliao, Inner Mongolia, China"]},{"name":"Affiliated Tongliao Clinical Medical College of Inner Mongolia Medical University","place":["Tongliao, Inner Mongolia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Liu","sequence":"additional","affiliation":[{"name":"Tongliao People\u2019s Hospital","place":["Tongliao, Inner Mongolia, China"]},{"name":"Affiliated Tongliao Clinical Medical College of Inner Mongolia Medical University","place":["Tongliao, Inner Mongolia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Sun","sequence":"additional","affiliation":[{"name":"Tongliao People\u2019s Hospital","place":["Tongliao, Inner Mongolia, China"]},{"name":"Affiliated Tongliao Clinical Medical College of Inner Mongolia Medical University","place":["Tongliao, Inner Mongolia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terigen","family":"Bao","sequence":"additional","affiliation":[{"name":"Tongliao People\u2019s Hospital","place":["Tongliao, Inner Mongolia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Wang","sequence":"additional","affiliation":[{"name":"Tongliao People\u2019s Hospital","place":["Tongliao, Inner Mongolia, China"]},{"name":"Affiliated Tongliao Clinical Medical College of Inner Mongolia Medical University","place":["Tongliao, Inner Mongolia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zheng","sequence":"additional","affiliation":[{"name":"Tongliao People\u2019s Hospital","place":["Tongliao, Inner Mongolia, China"]},{"name":"Affiliated Tongliao Clinical Medical College of Inner Mongolia Medical University","place":["Tongliao, Inner Mongolia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Wu","sequence":"additional","affiliation":[{"name":"Tongliao People\u2019s Hospital","place":["Tongliao, Inner Mongolia, China"]},{"name":"Affiliated Tongliao Clinical Medical College of Inner Mongolia Medical University","place":["Tongliao, Inner Mongolia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Chen","sequence":"additional","affiliation":[{"name":"Tongliao People\u2019s Hospital","place":["Tongliao, Inner Mongolia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyou","family":"Zhang","sequence":"additional","affiliation":[{"name":"Tongliao People\u2019s Hospital","place":["Tongliao, Inner Mongolia, China"]},{"name":"Affiliated Tongliao Clinical Medical College of Inner Mongolia Medical University","place":["Tongliao, Inner Mongolia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"117129","DOI":"10.1016\/j.taap.2024.117129","article-title":"Berberine attenuates ECM accumulation and the progression of acute liver failure through inhibition of NLRP3 inflammasome signalling","volume":"492","author":"Ali","year":"2024","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"3958","DOI":"10.1038\/s41598-025-34068-2","article-title":"An integrative computational approach for identification of NLRP3 inhibitors through machine learning, docking, dynamics and DFT analysis","volume":"16","author":"Alzarea","year":"2025","journal-title":"Sci. Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nri.2016.58","article-title":"Inflammasomes: mechanism of assembly, regulation and signalling","volume":"16","author":"Broz","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.tips.2025.04.007","article-title":"Targeting the NLRP3 inflammasome for inflammatory disease therapy","volume":"46","author":"Cabral","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"156897","DOI":"10.1016\/j.phymed.2025.156897","article-title":"Resveratrol reduces the activation of NLRP3 inflammasomes in rheumatoid arthritis through SIRT1 and ITGB \u03b1(5)\u03b2(1), especially in patients with high expression of ACPA","volume":"144","author":"Cai","year":"2025","journal-title":"Phytomedicine International Journal Phytotherapy Phytopharmacology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3389\/fmed.2017.00069","article-title":"Celastrol: a spectrum of treatment opportunities in chronic diseases","volume":"4","author":"Casc\u00e3o","year":"2017","journal-title":"Front. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s11658-023-00462-9","article-title":"The NLRP3 inflammasome: contributions to inflammation-related diseases","volume":"28","author":"Chen","year":"2023","journal-title":"Cell. Mol. Biol. Lett."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1850200","DOI":"10.1155\/crp\/1850200","article-title":"Estrogen alleviates myocardial ischemia-reperfusion injury by inhibiting NLRP3 inflammasome-mediated pyroptosis","volume":"2025","author":"Cheng","year":"2025","journal-title":"Cardiol. Res. Pract."},{"key":"B10","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41577-023-00849-x","article-title":"The NLR gene family: from discovery to present day","volume":"23","author":"Chou","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nm.3806","article-title":"A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases","volume":"21","author":"Coll","year":"2015","journal-title":"Nat. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41589-019-0277-7","article-title":"MCC950 directly targets the NLRP3 ATP-Hydrolysis motif for inflammasome inhibition","volume":"15","author":"Coll","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.tips.2022.04.003","article-title":"NLRP3 and pyroptosis blockers for treating inflammatory diseases","volume":"43","author":"Coll","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1161\/CIRCULATIONAHA.115.017611","article-title":"Anti-inflammatory treatment with colchicine in acute myocardial infarction: a pilot study","volume":"132","author":"Deftereos","year":"2015","journal-title":"Circulation"},{"key":"B15","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.jacbts.2024.12.012","article-title":"NLRP3 inflammasome inhibition by the novel bispecific antibody InflamAb attenuates atherosclerosis in apolipoprotein E-Deficient mice","volume":"10","author":"Delfos","year":"2025","journal-title":"JACC-Basic Transl. Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1161\/CIRCRESAHA.116.308030","article-title":"Chronic heart failure and inflammation: what do we really know?","volume":"119","author":"Dick","year":"2016","journal-title":"Circ. Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.intimp.2016.12.031","article-title":"Berberine, an isoquinoline alkaloid suppresses TXNIP mediated NLRP3 inflammasome activation in MSU crystal stimulated RAW 264.7 macrophages through the upregulation of Nrf2 transcription factor and alleviates MSU crystal induced inflammation in rats","volume":"44","author":"Dinesh","year":"2017","journal-title":"Int. Immunopharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.phrs.2018.09.021","article-title":"Curcumin and allopurinol ameliorate fructose-induced hepatic inflammation in rats via miR-200a-mediated TXNIP\/NLRP3 inflammasome inhibition","volume":"137","author":"Ding","year":"2018","journal-title":"Pharmacol. Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","first-page":"8041","DOI":"10.1073\/pnas.0611496104","article-title":"Cryopyrin\/NALP3 binds ATP\/dATP, is an ATPase, and requires ATP binding to mediate inflammatory signaling","volume":"104","author":"Duncan","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.2147\/JIR.S320912","article-title":"Resveratrol relieves gouty arthritis by promoting mitophagy to inhibit activation of NLRP3 inflammasomes","volume":"14","author":"Fan","year":"2021","journal-title":"J. Inflamm. Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"107133","DOI":"10.1016\/j.intimp.2020.107133","article-title":"The covalent NLRP3-inflammasome inhibitor oridonin relieves myocardial infarction induced myocardial fibrosis and cardiac remodeling in mice","volume":"90","author":"Gao","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e2300521","DOI":"10.1002\/advs.202300521","article-title":"Selective NLRP3 inflammasome inhibitor MCC950 suppresses inflammation and facilitates healing in vascular materials","volume":"10","author":"Grant","year":"2023","journal-title":"Adv. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1189\/jlb.3A0415-155RR","article-title":"Sulforaphane inhibits multiple inflammasomes through an Nrf2-independent mechanism","volume":"99","author":"Greaney","year":"2016","journal-title":"J. Leukoc. Biol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"14897","DOI":"10.1021\/acs.jmedchem.3c01398","article-title":"Discovery of clinical candidate NT-0796, a brain-penetrant and highly potent NLRP3 inflammasome inhibitor for neuroinflammatory disorders","volume":"66","author":"Harrison","year":"2023","journal-title":"J. Med. Chem."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1038\/s41467-018-04947-6","article-title":"Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity","volume":"9","author":"He","year":"2018","journal-title":"Nat. Commun."},{"key":"B27","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s41586-022-04467-w","article-title":"Structure of the NLRP3 decamer bound to the cytokine release inhibitor CRID3","volume":"604","author":"Hochheiser","year":"2022","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e8689","DOI":"10.15252\/emmm.201708689","article-title":"Tranilast directly targets NLRP3 to treat inflammasome-driven diseases","volume":"10","author":"Huang","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1084\/jem.20171419","article-title":"Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders","volume":"214","author":"Jiang","year":"2017","journal-title":"J. Experimental Medicine"},{"key":"B30","doi-asserted-by":"publisher","first-page":"9792","DOI":"10.1074\/jbc.M109.082305","article-title":"Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome","volume":"285","author":"Juliana","year":"2010","journal-title":"J. Biological Chemistry"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.3390\/antiox13091092","article-title":"A review of recent curcumin analogues and their antioxidant, anti-inflammatory, and anticancer activities","volume":"13","author":"Kaur","year":"2024","journal-title":"Antioxidants"},{"key":"B32","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1161\/CIRCULATIONAHA.110.982777","article-title":"Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia\/reperfusion injury","volume":"123","author":"Kawaguchi","year":"2011","journal-title":"Circulation"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.3390\/ijms20133328","article-title":"The NLRP3 inflammasome: an overview of mechanisms of activation and regulation","volume":"20","author":"Kelley","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1021\/acschembio.1c00218","article-title":"A probe for NLRP3 inflammasome inhibitor MCC950 identifies carbonic anhydrase 2 as a novel target","volume":"16","author":"Kennedy","year":"2021","journal-title":"ACS Chem. Biol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"A4366197","DOI":"10.1161\/circ.152.suppl_3.4366197","article-title":"Abstract 4366197: selnoflast reduces markers of systemic inflammation in participants with coronary artery disease and elevated C-reactive protein","volume":"152","author":"Kunder","year":"2025","journal-title":"Circulation"},{"key":"B36","doi-asserted-by":"publisher","first-page":"117711","DOI":"10.1016\/j.biopha.2024.117711","article-title":"The NLRP3-inflammasome inhibitor MCC950 improves cardiac function in a HFpEF mouse model","volume":"181","author":"Li","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"B37","doi-asserted-by":"publisher","first-page":"156257","DOI":"10.1016\/j.phymed.2024.156257","article-title":"Bioinformatics and molecular docking reveal cryptotanshinone as the active anti-inflammation component of qu-shi-xie-zhuo decoction by inhibiting S100A8\/A9-NLRP3-IL-1\u03b2 signaling","volume":"136","author":"Liao","year":"2025","journal-title":"Phytomedicine International Journal Phytotherapy Phytopharmacology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1161\/ATVBAHA.118.310958","article-title":"Novel antiatherosclerotic therapies","volume":"39","author":"Libby","year":"2019","journal-title":"Arteriosclerosis, Thrombosis, Vascular Biology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00395-014-0415-z","article-title":"TXNIP mediates NLRP3 inflammasome activation in cardiac microvascular endothelial cells as a novel mechanism in myocardial ischemia\/reperfusion injury","volume":"109","author":"Liu","year":"2014","journal-title":"Basic Res. Cardiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/JIR.S550023","article-title":"Predictive value of NLRP3 inflammasome activation for unstable plaques and major adverse cardiovascular events in coronary heart disease","volume":"19","author":"Liu","year":"2026","journal-title":"J. Inflamm. Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1002\/med.21751","article-title":"Biosynthesis, total synthesis, structural modifications, bioactivity, and mechanism of action of the quinone-methide triterpenoid celastrol","volume":"41","author":"Lu","year":"2021","journal-title":"Med. Res. Rev."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1002\/1873-3468.14091","article-title":"Resveratrol reduces cardiac NLRP3-inflammasome activation and systemic inflammation to lessen doxorubicin-induced cardiotoxicity in juvenile mice","volume":"595","author":"Maayah","year":"2021","journal-title":"FEBS Lett."},{"key":"B43","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/nrd.2018.97","article-title":"Targeting the NLRP3 inflammasome in inflammatory diseases","volume":"17","author":"Mangan","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"B44","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Reviews. Drug Discovery"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e14272","DOI":"10.1111\/acel.14272","article-title":"The NLRP3 inhibitor dapansutrile improves the therapeutic action of lonafarnib on progeroid mice","volume":"23","author":"Muela-Zarzuela","year":"2024","journal-title":"Aging Cell."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1021\/acs.jmedchem.6b00975","article-title":"The essential medicinal chemistry of curcumin","volume":"60","author":"Nelson","year":"2017","journal-title":"J. Med. Chem."},{"key":"B47","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1161\/CIRCRESAHA.124.325196","article-title":"LncRNA MIR181A1HG deficiency attenuates vascular inflammation and atherosclerosis","volume":"136","author":"Ni","year":"2025","journal-title":"Circ. Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00011-025-02058-9","article-title":"Clinical outcomes of anti-inflammatory therapies inhibiting the NLRP3\/IL-1\u03b2\/IL-6\/CRP pathway in coronary artery disease patients: a systemic review and meta-analysis of 37,056 individuals from 32 randomized trials","volume":"74","author":"Pan","year":"2025","journal-title":"Inflamm. Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"e003031","DOI":"10.1161\/JAHA.115.003031","article-title":"NLRP3 inflammasome expression and activation in human atherosclerosis","volume":"5","author":"Paramel Varghese","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"B51","doi-asserted-by":"publisher","first-page":"115915","DOI":"10.1016\/j.bcp.2023.115915","article-title":"NLRP3 inhibitors: unleashing their therapeutic potential against inflammatory diseases","volume":"218","author":"Ramalingam","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e014044","DOI":"10.1161\/JAHA.119.014044","article-title":"Targeting the NLRP3 inflammasome with inhibitor MCC950 prevents aortic aneurysms and dissections in mice","volume":"9","author":"Ren","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1093\/eurheartj\/ehw024","article-title":"Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin","volume":"37","author":"Ridker","year":"2016","journal-title":"Eur. Heart J."},{"key":"B54","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.1016\/j.jacc.2018.06.082","article-title":"Clinician's guide to reducing inflammation to reduce atherothrombotic risk: JACC review topic of the week","volume":"72","author":"Ridker","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B56","volume-title":"Emlenoflast (RG6346) Development Update","author":"Roche","year":"2025"},{"key":"B57","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.jacc.2017.12.037","article-title":"Tet2-Mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1\u03b2\/NLRP3 inflammasome","volume":"71","author":"Sano","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1001\/jama.2008.600","article-title":"Vitamins E and C in the prevention of cardiovascular disease in men: the physicians' health study II randomized controlled trial","volume":"300","author":"Sesso","year":"2008","journal-title":"JAMA"},{"key":"B59","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41586-019-1295-z","article-title":"Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome","volume":"570","author":"Sharif","year":"2019","journal-title":"Nature"},{"key":"B60","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.tibs.2016.10.004","article-title":"Pyroptosis: gasdermin-mediated programmed necrotic cell death","volume":"42","author":"Shi","year":"2017","journal-title":"Trends biochem. Sci."},{"key":"B61","doi-asserted-by":"publisher","first-page":"115784","DOI":"10.1016\/j.ejmech.2023.115784","article-title":"Discovery of NLRP3 inhibitors using machine learning: identification of a hit compound to treat NLRP3 activation-driven diseases","volume":"260","author":"Shi","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"B62","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.immuni.2024.03.012","article-title":"The NLR family of innate immune and cell death sensors","volume":"57","author":"Sundaram","year":"2024","journal-title":"Immunity"},{"key":"B63","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41589-019-0278-6","article-title":"MCC950 closes the active conformation of NLRP3 to an inactive state","volume":"15","author":"Tapia-Abell\u00e1n","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"865772","DOI":"10.3389\/fimmu.2022.865772","article-title":"Targeting NLRP3 inflammasome with Nrf2 inducers in central nervous system disorders","volume":"13","author":"Tastan","year":"2022","journal-title":"Front. Immunol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1422249","DOI":"10.3389\/fimmu.2024.1422249","article-title":"Screening NLRP3 drug candidates in clinical development: lessons from existing and emerging technologies","volume":"15","author":"Tengesdal","year":"2024","journal-title":"Front. Immunol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrcardio.2017.161","article-title":"The NLRP3 inflammasome in acute myocardial infarction","volume":"15","author":"Toldo","year":"2018","journal-title":"Nat. Reviews. Cardiol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ijcard.2016.02.043","article-title":"Inhibition of the NLRP3 inflammasome limits the inflammatory injury following myocardial ischemia-reperfusion in the mouse","volume":"209","author":"Toldo","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/FJC.0000000000000658","article-title":"The NLRP3 inflammasome inhibitor, OLT1177 (dapansutrile), reduces infarct size and preserves contractile function after ischemia reperfusion injury in the mouse","volume":"73","author":"Toldo","year":"2019","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1093\/eurheartj\/ehw247","article-title":"The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction","volume":"38","author":"van Hout","year":"2017","journal-title":"Eur. Heart J."},{"key":"B71","volume-title":"VTX2735 Phase II Trial Initiation Press Release","author":"Ventyx","year":"2025"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1322907","DOI":"10.3389\/fendo.2023.1322907","article-title":"Role of pyroptosis in diabetic cardiomyopathy: an updated review","volume":"14","author":"Wang","year":"2024","journal-title":"Front. Endocrinol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"00604","DOI":"10.1016\/j.jare.2025.08.013","article-title":"Quercetin attenuates tendon stem\/progenitor cell senescence and promotes aged tendon repair via AKT\/NF-\u03baB\/NLRP3-mediated mitophagy activation","author":"Wang","year":"2025","journal-title":"J. Adv. Res."},{"key":"B74","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/FJC.0000000000000931","article-title":"Phase 1B, randomized, double-blinded, dose escalation, single-center, repeat dose safety and pharmacodynamics study of the oral NLRP3 inhibitor dapansutrile in subjects with NYHA II-III systolic heart failure","volume":"77","author":"Wohlford","year":"2020","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1007\/s10787-024-01566-0","article-title":"The role of quercetin in NLRP3-associated inflammation","volume":"32","author":"Wu","year":"2024","journal-title":"Inflammopharmacology"},{"key":"B76","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.apsb.2022.09.014","article-title":"Costunolide covalently targets NACHT domain of NLRP3 to inhibit inflammasome activation and alleviate NLRP3-driven inflammatory diseases","volume":"13","author":"Xu","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"B77","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11883-025-01323-w","article-title":"Cholesterol crystals as triggers of NLRP3 inflammasome activation in atherosclerosis","volume":"27","author":"Yalcinkaya","year":"2025","journal-title":"Curr. Atheroscler. Rep."},{"key":"B78","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41419-019-1413-8","article-title":"Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors","volume":"10","author":"Yang","year":"2019","journal-title":"Cell. Death Dis."},{"key":"B79","doi-asserted-by":"publisher","first-page":"116952","DOI":"10.1016\/j.taap.2024.116952","article-title":"Berberine alleviated contrast-induced acute kidney injury by mitophagy-mediated NLRP3 inflammasome inactivation in a mice model","volume":"486","author":"Yang","year":"2024","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s10753-024-02060-z","article-title":"Celastrol regulates the hsp90-NLRP3 interaction to alleviate rheumatoid arthritis","volume":"48","author":"Yang","year":"2025","journal-title":"Inflammation"},{"key":"B80","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1161\/CIRCULATIONAHA.118.035202","article-title":"Enhanced cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation","volume":"138","author":"Yao","year":"2018","journal-title":"Circulation"},{"key":"B81","doi-asserted-by":"publisher","first-page":"67300","DOI":"10.18632\/oncotarget.18619","article-title":"Celastrol ameliorates inflammation through inhibition of NLRP3 inflammasome activation","volume":"8","author":"Yu","year":"2017","journal-title":"Oncotarget"},{"key":"B82","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1021\/acs.jmedchem.0c01743","article-title":"Berberine directly targets the NEK7 protein to block the NEK7-NLRP3 interaction and exert anti-inflammatory activity","volume":"64","author":"Zeng","year":"2021","journal-title":"J. Med. Chem."},{"key":"B83","doi-asserted-by":"publisher","first-page":"e0341839","DOI":"10.1371\/journal.pone.0341839","article-title":"Multi-omics analysis reveals STING activation mediates NLRP3-related pyroptosis and exacerbates myocardial ischemia-reperfusion injury","volume":"21","author":"Zhang","year":"2026","journal-title":"PLoS One"},{"key":"B84","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1021\/acschembio.3c00777","article-title":"Integrated proteomics characterization of NLRP3 inflammasome inhibitor MCC950 in monocytic cell line confirms direct MCC950 engagement with endogenous NLRP3","volume":"19","author":"Zhao","year":"2024","journal-title":"ACS Chem. Biol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"e2400459","DOI":"10.1002\/ardp.202400459","article-title":"MCC950 as a promising candidate for blocking NLRP3 inflammasome activation: a review of preclinical research and future directions","volume":"357","author":"Zheng","year":"2024","journal-title":"Arch. Pharm. Weinh."},{"key":"B86","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.biopha.2017.03.003","article-title":"Berberine inhibits palmitate-induced NLRP3 inflammasome activation by triggering autophagy in macrophages: a new mechanism linking berberine to insulin resistance improvement","volume":"89","author":"Zhou","year":"2017","journal-title":"Biomed. and Pharmacotherapy = Biomedecine and Pharmacotherapie"},{"key":"B87","doi-asserted-by":"publisher","first-page":"116706","DOI":"10.1016\/j.biopha.2024.116706","article-title":"Sulforaphane decreases oxidative stress and inhibits NLRP3 inflammasome activation in a mouse model of ulcerative colitis","volume":"175","author":"Zhou","year":"2024","journal-title":"Biomed. Pharmacother."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1861169\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:45:19Z","timestamp":1782276319000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1861169\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":88,"alternative-id":["10.3389\/fphar.2026.1861169"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1861169","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"article-number":"1861169"}}